Genetically determined polymorphisms in drug oxidation (Q44947499)

7 December 2017

title

Genetically determined polymorphisms in drug oxidation (English)

1 reference

7 December 2017

Jacqz E

1

1 reference

7 December 2017

Hall SD

series ordinal

2

1 reference

7 December 2017

Branch RA

series ordinal

3

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 September 1986

1 reference

7 December 2017

1 reference

7 December 2017

volume

6

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

1020-1032

1 reference

The metabolism of [14C]-debrisoquine in man

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Genetically determined oxidation capacity and the disposition of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Defective metabolism of metoprolol in poor hydroxylators of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Quinidine-induced rise in ajmaline plasma concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Quantification of side-effects of beta-adrenoceptor blockers using visual analogue scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

Contribution of Environmental Factors to Variability in Human Drug Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Defective oxidation of drugs: pharmacokinetic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Genetically determined variability in acetylation and oxidation. Therapeutic implications

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Genetics of drug transformation

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Pharmacogenetic perspectives: genes, drugs and disease

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Influence of the defective metabolism of sparteine on its pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Hypotensive response to debrisoquine and hydroxylation phenotype

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Deficient metabolism of debrisoquine and sparteine

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

A case of deficiency of N-hydroxylation of amobarbital

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

N-Glucosidation of amobarbital in the cat

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Variation in amobarbital metabolism: evaluation of a simplified population study

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Inheritance of phenytoin hypometabolism: a kinetic study of one family

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Why hypertensive patients vary in their response to oral debrisoquine

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Distinctive patterns of amobarbital metabolites

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Multiple forms of cytochrome P450 in the microsomal monooxygenase system

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Isolation and purification of cytochrome P-450, and the existence of multiple forms

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Multiple forms of cytochrome P-450 and the importance of molecular biology and evolution

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Sparteine metabolism in Canadian Caucasians

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Debrisoquine hydroxylation capacity: problems of assessment in two populations

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Ethnic differences in drug metabolism

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Polymorphisms of Oxidation at Carbon Centers of Drugs and Their Clinical Significance

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Cytochrome P1-450 structural gene in mouse, rat, and rabbit: differences in DNA methylation and developmental expression of mRNA.

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Factors controlling the expression of genes coding for drug-metabolizing enzymes

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

The Ah receptor: Binding specificity only for foreign chemicals?

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Acetophenetidin-induced methemoglobinemia

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Polymorphism of carbon oxidation of drugs and clinical implications

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Metabolic oxidation phenotypes as markers for susceptibility to lung cancer

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Oxidation phenotype--a major determinant of metoprolol metabolism and response

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Polymorphic metabolism of metoprolol: clinical studies.

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Genetic impairment of phenformin metabolism

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Influence of the Genetically Controlled Deficiency in Debrisoquine Hydroxylation on Antipyrine Metabolite Formation

1 reference

https://api.crossref.org/works/10.1002/HEP.1840060534

7 January 2021

Identifiers

DOI

10.1002/HEP.1840060534

1 reference

7 December 2017

1 reference